Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 Pharmacokinetics in Healthy Japanese and Non-Japanese Adults
NCT05641311Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atn-224 in Wilson disease (WD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration at Day 11. Started Feb 2019; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT05641311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641311.